Compare CRNX & ZETA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | ZETA |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2018 | 2021 |
| Metric | CRNX | ZETA |
|---|---|---|
| Price | $33.97 | $22.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $76.75 | $27.67 |
| AVG Volume (30 Days) | 1.2M | ★ 8.3M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.16 |
| EPS | N/A | ★ N/A |
| Revenue | $1,039,000.00 | ★ $1,304,668,000.00 |
| Revenue This Year | $720.10 | $37.35 |
| Revenue Next Year | $184.67 | $16.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.72 |
| 52 Week Low | $25.83 | $12.10 |
| 52 Week High | $57.99 | $25.95 |
| Indicator | CRNX | ZETA |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 59.58 |
| Support Level | $33.36 | $17.26 |
| Resistance Level | $37.23 | $22.19 |
| Average True Range (ATR) | 1.36 | 1.52 |
| MACD | -0.23 | 0.38 |
| Stochastic Oscillator | 29.09 | 54.18 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing. The company operates in U.S, where it generates maximum revenue and Internationally as well.